American Heart Journal
Volume 157, Issue 1 , Pages 97-101 , January 2009

Within-person variation of the plasma concentration of B-type natriuretic peptide: Safety range in stable patients with heart failure

  • Yasuko Takeda, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Yutaka Takeda, MD, Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho, Mizuho, Nagoya, Aichi 467-8601, Japan.
    • ,
  • Yutaka Takeda, MD
    • ,
  • Shogo Suzuki, MD
    • ,
  • Genjiro Kimura, MD

Received 5 February 2008 ,Accepted 2 September 2008.

References 

  1. Bettencourt P, Ferreira A, Dias P, et al. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology. 2000;93:19–25
  2. Lainchbury JG, Campbell E, Frampton CM, et al. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003;42:728–735
  3. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  4. Krüger S, Graf J, Kunz D, et al. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol. 2002;40:718–722
  5. Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001;38:1934–1941
  6. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentrations in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509–516
  7. Wu AH. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J. 2006;152:828–834
  8. Fokkema M, Herrmann Z, Muskiet F, et al. Reference change values for brain natriuretic peptides revisited. Clin Chem. 2006;52:1602–1603
  9. Shimosako K, Takahashi A, Saitou T, et al. Evaluation of automated chemiluminescent enzyme immunoassay analyzer exclusive kit “MI02 Shionogi BNP”. Igaku To Yakugaku. 2005;53:355–360[Japanese]
  10. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135–160
  11. Mantha S, Roizen MF, Fleisher LA, et al. Comparing methods of clinical measurement: reporting standards for Bland and Altman anlaysis. Anesth Analg. 2000;90:593–602
  12. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2002;106:2454–2458
  13. Talwar DK, Azharuddin MK, Williamson C, et al. Biological variation of vitamins in blood of healthy individuals. Clin Chem. 2005;51:2145–2150
  14. Sheth T, Parker T, Block A, et al. Comparison of the effects of omapatrilat and lisnopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol. 2002;90:496–500
  15. Wu AH, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003;92:628–631
  16. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patents with heart failure. Eur J Heart Fail. 2004;6:355–358
  17. Bruins S, Fokkema MR, Romer JW, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem. 2004;50:2052–2058
  18. O'Hanlon R, O'Shea P, Ledwidge M, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail. 2007;13:50–55
  19. Schou M, Gustafsson F, Nielsen PH, et al. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail. 2007;9:68–74
  20. Fitzgerald RL, Cremo R, Gardetto N, et al. Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Am Heart J. 2005;150:471–477
  21. Melzi d'Eril G, Tagnochetti T, Nauti A, et al. Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. Clin Chem. 2003;49:1554–1555
  22. Araújo JP, Azevedo A, Lourenço P, et al. Intraindividual variation of amino-terminal pro–B-type natriuretic peptide levels in patients with stable heart failure. Am J Cardiol. 2006;98:1248–1250
  23. Wu AH, Packer M, Smith A, et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem. 2004;50:867–873

PII: S0002-8703(08)00745-X

doi: 10.1016/j.ahj.2008.09.002

American Heart Journal
Volume 157, Issue 1 , Pages 97-101 , January 2009

Article Tools

* Image Usage & Resolution